VanEck Associates Portfolio holdings
AUM
$88.3B
1-Year Return
29.35%
This Quarter Return
+3.83%
1 Year Return
+29.35%
3 Year Return
+120.6%
5 Year Return
+164.76%
10 Year Return
+545.37%
AUM
$20.3B
AUM Growth
+$699M
(+3.6%)
Cap. Flow
+$219M
Cap. Flow
% of AUM
1.08%
Top 10 Holdings %
Top 10 Hldgs %
24.84%
Holding
742
New
18
Increased
309
Reduced
385
Closed
26
Top Buys
| 1 |
Schlumberger
SLB
|
$85.9M |
| 2 |
Alamos Gold
AGI
|
$61.4M |
| 3 |
Halliburton
HAL
|
$59.4M |
| 4 |
Gold Fields
GFI
|
$42.5M |
| 5 |
Rio Tinto
RIO
|
$41.3M |
Top Sells
| 1 |
Newmont
NEM
|
$115M |
| 2 |
B
Barrick Mining Corporation
B
|
$99.2M |
| 3 |
Franco-Nevada
FNV
|
$83.5M |
| 4 |
Freeport-McMoran
FCX
|
$73.1M |
| 5 |
GG
Goldcorp Inc
GG
|
$62.5M |
Sector Composition
| 1 | Materials | 50.09% |
| 2 | Energy | 18.24% |
| 3 | Healthcare | 7.4% |
| 4 | Technology | 5.44% |
| 5 | Consumer Discretionary | 2.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Bausch Health
BHC
$2.72B
| $14.3M | 0.07% |
689,136
-7,525
| -1% | -$156K |
|
202
Qorvo
QRVO
$8.61B
| $14.3M | 0.07% |
214,003
+57,966
| +37% | +$3.86M |
|
203
Viatris
VTRS
$12.2B
| $14.1M | 0.07% |
332,533
-56,614
| -15% | -$2.4M |
|
204
Grifois
GRFS
$6.89B
| $14.1M | 0.07% |
613,577
-304,099
| -33% | -$6.97M |
|
205
Toro Company
TTC
$7.99B
| $14M | 0.07% |
214,199
+2,302
| +1% | +$150K |
|
206
Novo Nordisk
NVO
$245B
| $13.9M | 0.07% |
516,524
-57,822
| -10% | -$1.55M |
|
207
AbbVie
ABBV
$375B
| $13.8M | 0.07% |
142,782
-36,237
| -20% | -$3.5M |
|
208
GSK
GSK
$81.5B
| $13.8M | 0.07% |
311,105
+36,336
| +13% | +$1.61M |
|
|
DCUD
209
DELISTED
Dominion Energy, Inc 2016 Series A Corporate Units
DCUD
| $13.7M | 0.07% |
264,956
+24,532
| +10% | +$1.27M |
|
210
Novartis
NVS
$251B
| $13.6M | 0.07% |
180,605
-2,230
| -1% | -$168K |
|
211
Vale
VALE
$44.4B
| $13.4M | 0.07% |
1,099,349
-264,359
| -19% | -$3.23M |
|
212
Sanofi
SNY
$113B
| $13.4M | 0.07% |
312,200
+34,208
| +12% | +$1.47M |
|
213
Johnson & Johnson
JNJ
$430B
| $13.3M | 0.07% |
95,341
-9,803
| -9% | -$1.37M |
|
|
ANTX
214
DELISTED
Anthem, Inc.
ANTX
| $13.2M | 0.07% |
236,569
+21,903
| +10% | +$1.23M |
|
215
FS KKR Capital
FSK
$5.08B
| $12.8M | 0.06% |
434,385
+20,015
| +5% | +$588K |
|
|
CAVM
216
DELISTED
Cavium, Inc.
CAVM
| $12.8M | 0.06% |
152,311
+48,555
| +47% | +$4.07M |
|
217
Ternium
TX
$6.79B
| $12.4M | 0.06% |
394,079
-102,281
| -21% | -$3.23M |
|
|
VEDL
218
DELISTED
Vedanta Limited American Depostary Shares (Each representing four equity shares)
VEDL
| $12.4M | 0.06% |
593,645
-154,585
| -21% | -$3.22M |
|
|
MSCC
219
DELISTED
Microsemi Corp
MSCC
| $12.3M | 0.06% |
237,381
+57,357
| +32% | +$2.96M |
|
220
AGNC Investment
AGNC
$10.8B
| $12.1M | 0.06% |
600,086
+110,665
| +23% | +$2.23M |
|
221
United Therapeutics
UTHR
$18.1B
| $11.7M | 0.06% |
79,383
-43,717
| -36% | -$6.47M |
|
222
Jazz Pharmaceuticals
JAZZ
$7.86B
| $11.7M | 0.06% |
86,919
+3,709
| +4% | +$499K |
|
|
KMI.PRA
223
DELISTED
Kinder Morgan, Inc.
KMI.PRA
| $11.5M | 0.06% |
302,808
+28,036
| +10% | +$1.06M |
|
224
Alnylam Pharmaceuticals
ALNY
$59.2B
| $11M | 0.05% |
86,699
-68,486
| -44% | -$8.7M |
|
225
AGCO
AGCO
$8.28B
| $10.9M | 0.05% |
152,849
-633
| -0.4% | -$45.2K |
|